--- title: "Hong Kong stock movement: DIAGENS-B rose by 12.09%, driven by the dual benefits of financial blockchain and industrial large models boosting the stock price" type: "News" locale: "en" url: "https://longbridge.com/en/news/282130450.md" description: "DIAGENS-B rose 12.09%; MicroPort Medical fell 2.88%, with a transaction volume of HKD 112 million; Gensun Bridge fell 1.30%, with a transaction volume of HKD 106 million; MicroPort Robotics-B fell 0.73%, with a transaction volume of HKD 67.39 million; Precision Medical-B fell 5.32%, with a market value of HKD 21.3 billion" datetime: "2026-04-09T03:58:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282130450.md) - [en](https://longbridge.com/en/news/282130450.md) - [zh-HK](https://longbridge.com/zh-HK/news/282130450.md) --- # Hong Kong stock movement: DIAGENS-B rose by 12.09%, driven by the dual benefits of financial blockchain and industrial large models boosting the stock price **Hong Kong Stock Movement** DIAGENS-B rose by 12.09%. Based on recent key news: 1. On April 6, the company proactively adjusted its risk control strategy, enhancing its risk prevention capabilities, and launched the first financial blockchain management platform in the national consumer finance industry. This move boosted market confidence in the company's future development, driving the stock price up. Source: Zhitong Finance 2. On April 6, large industrial models became the core driving force for promoting new industrialization, with the market size expected to exceed 42 billion yuan by 2030. The company's technological innovation and industrial implementation capabilities in this field are viewed positively by the market, further uplifting the stock price. Source: Zhitong Finance 3. On April 9, DIAGENS-B's strong performance in the capital market attracted more investor attention, with trading volume significantly increasing, pushing the stock price higher. Source: Zhitong Finance. The market prospects for large industrial models are broad, with noticeable capital inflow. **Stocks with High Trading Volume in the Industry** MicroPort Medical fell by 2.88%. Based on recent key news: 1. On April 9, the technical chart of MicroPort Medical showed a weak pattern, with MACD death cross momentum slowing down. The pharmaceutical sector is under pressure from policy adjustments and a slowdown in overseas market demand, impacting the company's profitability. Source: Zhitong Finance 2. On April 8, a report from Bank of America Securities pointed out that MicroPort Medical has strong growth potential in overseas markets and surgical robot business. Although the target price was lowered to HKD 13.9, the "Buy" rating was reaffirmed. Source: Zhitong Finance 3. On April 7, the pressure from convertible bonds and debts that MicroPort Medical needs to redeem increased. Management stated that it would raise the operating profit margin target to 4% and bet on overseas market expansion. Source: Daily Economic News. The impact of policy adjustments on the pharmaceutical sector is significant. Guochuang Tongqiao fell by 1.30%. Based on recent key news: 1. On April 9, Guochuang Tongqiao recorded large transactions, with the transaction price 8.77% lower than the previous closing price, leading to a decline in stock price. This transaction involved 1 lot of 1.4 million shares in pre-market trading and 1 lot of 1 million shares in non-automatic matching, totaling HKD 50.4 million. Source: Economic Information Daily 2. On April 8, Guochuang Tongqiao announced a change in the agreement of concerted action, stating that Zhong Shengping and his wholly-owned WEA are no longer members of the concerted action. This change is considered not to have a significant impact on the company's financial status or operations, but may raise market concerns about the company's governance structure. Source: Economic Information Daily. The Hong Kong stock market has been volatile recently and requires attention. MicroPort Robotics-B fell by 0.73%. Based on recent key news: 1. On April 8, JP Morgan raised the target price for MicroPort Robotics-B to HKD 42 and maintained the "Overweight" rating, indicating that the company is transitioning from "commercial validation" to "profit release," setting clear revenue and profit targets. This news provided support for the stock price but did not fully offset market volatility. 2. On April 8, Zhitong Finance reported that the overseas market demand for MicroPort Robotics-B is strong, especially in Europe, Asia, and Latin America, with expectations to install at least 200 surgical robots throughout the year, demonstrating the company's growth potential in the global market On April 7th, MicroPort Scientific Corporation's management stated at an earnings communication meeting that the company faces financial constraints and needs to achieve a full-year net profit target of USD 90 million by 2026, increasing market attention on the company's profitability. The medical technology industry has strong growth potential, with a focus on policy changes. **Stocks ranked among the top in industry market capitalization** MicroPort Scientific Corporation-B fell by 5.32%. Based on recent key news: 1. On April 7th, GF Securities released a research report, predicting that MicroPort Scientific Corporation-B's operating revenue will grow significantly over the next three years and gave it a "Buy" rating. The company's rapid layout in domestic and international markets and the launch of new products are considered the main drivers of performance growth. However, market expectations for its future profitability may have been overly reflected, leading to a short-term adjustment in stock prices. 2. On April 7th, several new products from MicroPort Scientific Corporation-B received important certifications, including NMPA and EU CE certifications. These certifications help the company’s market position in minimally invasive surgery, but the market may take a wait-and-see attitude towards its commercialization progress in the short term. 3. On April 7th, the company's overall expense ratio was significantly adjusted, with declines in R&D expense ratio and management expense ratio showing the company's effectiveness in cost control. However, the market may have concerns about its future R&D investment and innovation capabilities. The medical device industry is highly competitive, and policy impacts are significant ### Related Stocks - [02526.HK](https://longbridge.com/en/quote/02526.HK.md) ## Related News & Research - [09:08 ETUnionfab Reduces Low-Volume Metal Parts Production from 30 Days to as Fast as 5 Days](https://longbridge.com/en/news/286776856.md) - [Are Wall Street Analysts Bullish on PPG Industries Stock?](https://longbridge.com/en/news/287068283.md) - [WEG opens coating manufacturing site in Wisconsin as US expansion accelerates](https://longbridge.com/en/news/287103865.md) - [CMOC Group (CMCLF): New Buy Recommendation for This Basic Materials Giant](https://longbridge.com/en/news/286625840.md) - [Thyssenkrupp to close Indiana automotive site](https://longbridge.com/en/news/286718485.md)